Quadriceps muscle atrophy and inflammatory markers in COPD patients

CURRENT STATUS: UNDER REVIEW

Majid Ahmadi
Tabriz University of Medical Sciences
Corresponding Author
ORCiD: 0000-0003-4787-5261

Masoud Nazemiyeh
Tabriz University of Medical Sciences

Mahnaz Ghaebi
Tabriz University of Medical Sciences

Haleh Mikaeili
Tabriz University of Medical Sciences

Mohammadkazem Tarzamani
Tabriz University of Medical Sciences

Hamed Valizadeh
Urmia University of Medical Sciences
Corresponding Author

Saeed Aslani
Tehran University of Medical Sciences

DOI: 10.21203/rs.2.18693/v1

SUBJECT AREAS
Pulmonology
Immunology

KEYWORDS
COPD, Quadriceps muscle, C-reactive protein, Interleukin-1β,
Interleukin-6, Tumor necrosis factor-α
Abstract

Background

COPD (chronic obstructive pulmonary disease) is a systemic chronic inflammatory disease manifested by increased proinflammatory protein and cytokine levels. In this study, we aimed to investigate whether there is any correlation between systemic inflammatory mediators (CRP, ESR, PCT, IL-6, IL-1β, and TNF-α) and quadriceps muscle atrophy in patients with COPD.

Methods

The study group included forty patients with consecutive COPD followed at the Outpatient Pulmonology Unit of Imam Reza Hospital, Tabriz, Iran. Depth of quadriceps muscle was measured by B-mode ultrasonography using an 8 MHz 5.6 cm linear transducer array. Serum levels of CRP, PCT, IL-1β, IL-6 and TNF-α and the ESR were also measured. All patients were evaluated in three stages; the first day of mechanical ventilator admission, 48 hours later and at the seventh day.

Results

The results showed that the depth of quadriceps muscle on the seventh day after mechanical ventilator admission was significantly lower than of the first day ($P = 0.0008$). Statistical analysis showed a significant difference between the level of all systemic biomarkers on day 1 and day 7 ($P < 0.05$). The correlation study showed the significant negative associations between systemic inflammation markers and depth of quadriceps muscle. We found that the increased level of systemic inflammation biomarkers such as ESR, CRP and PCT were associated with reduced quadriceps depth in COPD patients. Moreover, evaluation of proinflammatory cytokines in COPD patients showed that the elevated IL-1β, IL-6, and TNF-α levels
were associated with quadriceps atrophy.

**Conclusion**

The main finding of this study is the positive correlation of systemic biomarkers of inflammation with quadriceps muscle atrophy in COPD patients over 7 days of mechanical ventilator admission.

**Background**

Many patients with chronic obstructive pulmonary disease (COPD) are recognized with cachexia or skeletal muscle dysfunction [1]. COPD-related reduction in muscle strength plays an important role in poor exercise performance [2] and is associated with increased healthcare consumption and mortality [3]. Whilst the pathophysiology of skeletal muscle dysfunction and wasting is multi-factorial, inactivity is likely to play a key role. Evidence suggests that inactivity is probably linked to multi-factorial pathophysiology of skeletal muscle dysfunction and wasting. Reduced muscle strength is more readily demonstrable in the lower limbs [4] of COPD patients/ Muscle weakness is more detectable in the lower limbs of patients with COPD and this can contribute to a “downward disease spiral” of loss of muscle strength, in which progressive dyspnoea leads to more sedentary lifestyle and locomotor muscles de-conditioning, and thus further limiting physical activities [5]. Of note, reduced exercise capacity correlates with increased COPD dyspnoea based on the MRC (Medical Research Council) dyspnoea scale with preserved whole body fat-free mass (FFM) indices/ [6]. The outcome of patient's pulmonary rehabilitation goals is to improve exercise performance which is assumed to increase muscle strength and endurance [7]. However, the international guidelines
recommend the use of pulmonary rehabilitation for COPD patients with a MRC
dyspnoea grade of > 3/ According to the international guidelines, patients with
COPD, of MRC dyspnoea grade of > 3 are currently recommended for the use of
pulmonary rehabilitation [8].

It has been noted that systemic inflammatory markers including IL-1 (interleukin-1), IL-6 (interleukin-6), TNF-α (tumor necrosis factor-α), CRP (C reactive protein) and PCT (procalcitonin) show an increase in COPD patients and are clearly associated to the systemic manifestations of the disease. CRP is an acute-phase protein biomarker of systemic inflammation that serves as a commonly used measure of disease severity. COPD patients often show high plasma levels of CRP that is a risk factor for increased mortality [9]. It is believed that CRP level is a measure of cardiovascular risk prediction and most likely to be of value in independently predicting death due to COPD [9]. Elevated levels of CRP are also associated with clinically important outcomes including exercise tolerance [10], health status [11], and muscle strength [12]. The synthesis of CRP is induced by inflammation associated cytokines such as IL-6 in hepatocytes [13]. Thus, IL-6 and CRP concentrations have been reported to correlate with COPD [13]. Furthermore, both IL-1β and TNF-α have been demonstrated to implicate in the muscle wasting and weight reduction observed in patients with COPD [14] and consistently studies have found high circulating levels of TNF-α and its cognate receptors in COPD patients [14]. There is much evidence that IL-1β and TNF-α are cytokines associated with IL-6 and CRP levels [12].

Although peripheral muscle weakness has a multifactorial etiology, a key concept is that systemic inflammation is strongly linked to muscle dysfunction [15]. COPD patients suffering from decreased quadriceps muscle strength, during exacerbation,
are more likely to have an increased plasma IL-β [15], IL-6 and TNF-α levels suggesting an inverse correlation between quadriceps muscle strength and systemic inflammatory mediators [12]. However, many studies have focused on lower limb muscles [16] [17] results of a previous study reported that relative intensity of movements in arm was lower in COPD patients than that of healthy control subjects [18]. Nevertheless, the contribution of systemic inflammatory biomarkers to strength in specific muscles is not clearly defined in these patients. The purposes of the present study was therefore to examine whether there is any correlation between mediators of systemic inflammation (CRP, ESR, PCT, IL-1β, IL-6 and TNF-α) and quadriceps muscle atrophy in patients with COPD.

Method

Study Patients

The study population included forty patients with consecutive COPD followed at the Outpatient Pulmonology Unit of Imam Reza Hospital, Tabriz, Iran. Eligibility criteria included patients that meet criteria for COPD based on the guidelines established in the Global Initiative for Chronic Obstructive Lung Disease. These criteria include an increase in FEV1 of 15% or 200 mL after inhalation of a β2-agonist and a post bronchodilator forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) ratio 0.70. Patients diagnosed with other chronic diseases (ie, diabetes, renal failure, or cancer) or other respiratory disease (ie, asthma, bronchiectasis, bronchiolitis, or tuberculosis); and those with oral steroid use or exacerbations in the 3 months before enrollment in the study were excluded. All patients were evaluated in three stages; the first day of admission, 48 hours later and at the seventh day. Each participant signed a written informed consent form
and was made aware of the study procedures based on ethical approval by the Research Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1396.134). Demographic data of patients are summarized in Table 1.

**Muscle Thickness (MT) measurements by ultrasonography**

Measurement of quadriceps muscle depth muscle were made by B-mode ultrasonography using an 8 MHz 5.6 cm linear transducer array (PLM805, Toshiba Medical Systems, Crawley, UK), as performed by de Bruin et al. [19]. The transducer was placed perpendicular to the long axis of the thigh on its superior aspect, three-fifths of the distance from the anterior superior iliac spine to the superior patellar border. This was the highest point in the thigh that the entire rectus femoris cross-section could be visualized in a single field in all subjects; other muscles of the quadriceps group could not be encompassed in this manner. During the imaging the participants were made to lie supine with one leg extended passively. Care was taken using excess contact gel to ensure minimal distortion of the underlying tissue. Visual feedback was used to minimize oblique imaging to obtain the cross-section smallest images. Scanning depth was set to where the femur could be discerned for orientation. Muscle septa were delineated through the gentle contraction-relaxation cycles before image acquisition. Quadriceps muscle depth was measured by a planimetric technique which was taken following the inner echogenic line of the rectus femoris was outlined by a movable cursor on a frozen image. An average of three consecutive measurements within 10% was performed to outline the depth of quadriceps muscle.

**Blood collection and analysis**

Peripheral blood was collected early morning from each fasting participant at three
time points (at first day, 48 hours later and at the day 7) and the plasma were then stored at -80°C. IL-1β, IL-6 and TNF-α were assessed by enzyme linked immunosorbent assay (ELISA) using high-sensitivity commercial kits (BioSource International Inc, Camarillo, CA, USA). CRP and PCT levels were measured by high-sensitivity particle-enhanced immunonephelometry (CardioPhase, Dade Behring Marburg GmbH, Marburg, USA), with a lower detection limit of 0.007 mg/L. All assessments were performed in duplicate.

**Statistical analysis**

Analyses were performed using GraphPad Prism1 Version 7.0 (GraphPad Software Inc., San Diego, CA, USA). Results are reported as means and standard deviations or median interquartile range (25%-75%). Between groups analyses using ANOVA and Post HOC Pair wise comparison were employed. We performed an association analysis between inflammatory markers of ESR, PCT, CRP, IL-1β, IL-6, TNF-α and quadriceps muscle atrophy using multiple linear regression with robust standard errors with adjustment for potential confounders. P-values below 0.05 were considered statistically significant.

**Results**

In this study, 40 patients were studied. The mean and standard deviation of the subjects were 65.83 ± 15.6 years. 17 (42.5%) patients were female and 23 (57.5%) were male. It should be noted that this number included only patients who had been hospitalized for at least 7 days, and 40 patients, including those who had been discharged or died earlier than 7 days, were not due to patients who had died or died from the community We left the statistics and replaced the new patient. Participant characteristics are shown in table 1.
The results of quadriceps muscle atrophy

In this stage of the study, ultrasonography was performed to obtain the degree of atrophy of the quadriceps muscle of the patients, so that the patients underwent ultrasonography of the quadriceps muscle in the first day after mechanical ventilator admission, and once 48 hours later from admission and once on the seventh day, ultrasound was performed.

The average depth of quadriceps muscle 40 patients in ultrasound of the first day was \(20.26 \pm 6.976\) in the second time of ultrasound \(16.64 \pm 6.248\) and in the third time ultrasound was \(14.33 \pm 5.179\), indicating a decrease in the depth and thickness of the muscle after admission. Statistical analysis of the results showed that the depth of muscle on the seventh day was significantly lower than the first day \((P = 0.0008)\). However, the depth of muscle was not significantly different at the second time with ultrasound than the first time and in the third time, compared to the second time. The results of this step are presented in Fig 1 and Table 2.

The results of inflammatory factors evaluation

The results of the ESR test in the first day were \(54.43 \pm 27.06\) in the second time, \(41.83 \pm 20.65\) and in 7 days after admission, it was \(37.15 \pm 14.66\). Statistical analysis showed a statistically significant difference between ESR on day 1 and day 7 \((P = 0.0013)\) and day 1 compared to day 2 with \(P\) value = 0.025 (Fig 2a and Table 2).

The results of the CRP test in the first day was \(37.2 \pm 18.026\) in the second phase, was \(26.14 \pm 16.29\) and \(26.25 \pm 11.26\) at the 7 days after admission. Statistical analysis showed a significant difference between CRP level on day 1 and day 7 with \(P\) value = 0.0013 and CRP on day 1 and day 2 with \(P\) value = 0.022 (Fig 2b and Table 2).
Also the result of the PCT test in the first day was 17.98 ± 14.19 for the second time, 7.348 ± 6.516, and at the final time, it was 6.925 ± 6.27. Statistical analysis showed a significant difference between PCT levels on day 1 and day 7 with a \( P \) value = 0.016 and PCT on day 1 and day 2 with a \( P \) value = 0.025 (Fig 2c and Table 2).

**The results of proinflammatory cytokine evaluation**

IL-1\( \beta \) secretion level of serum in the first day was 14.43 ± 8.04 pg/ml in the second day, 13.79 ± 6.61 pg/ml and in 7 days after admission, it was 16.1 ± 9.02 pg/ml. There was no statistically significant difference in the secretion level of IL-1\( \beta \) in three time (Fig 3a and Table 2).

IL-6 secretion level of serum in the first day was 3.96 ± 2.24 pg/ml in the second day, 3.65 ± 1.86 pg/ml and in 7 days after admission, it was 4.25 ± 2.44 pg/ml. There was no statistically significant difference in the secretion level of IL-6 in three time (Fig 3b and Table 2).

TNF-\( \alpha \) concentration level of serum in the first time was 167.9 ± 65.08 pg/ml in the second time, 155.6 ± 85.12 pg/ml and in 7 days after admission, it was 194.7 ± 99.61 pg/ml. There was no statistically significant difference in the secretion level of TNF-\( \alpha \) in three time of measurement (Fig 3c and Table 2).

**Correlation between various inflammatory factors and quadriceps muscle atrophy**

As manifested by the results, there was a positive correlation between the reduction of muscle depth in the quadriceps of patients and the Early rate of ESR, CRP and PCT. This correlation for ESR was statistically significant with \( P \) value <0.0001 and \( r = 0.698 \) and for CRP was statistically significant with \( P \) value =0.4nd to \( r = 0.53 \). Also, the correlation between quadriceps atrophy and PCT was statistically
significant with *P* value <0.0001 and *r* = 0.786 (Fig 4).

In this study we also assessed correlation between early proinflammatory cytokine and quadriceps muscle atrophy. It was found that there was a positive correlation between the quadriceps atrophy of COPD patients and the early concentration of IL-1β, IL-6 and TNF-α. This correlation for IL-1β was statistically significant with *P* value =0.032 and *r* = 0.338 and for IL-6 was statistically significant with *P* value =0.0013 nd to *r* = 0.49. Also, the correlation between quadriceps atrophy and TNF-α was statistically significant with *P* value =0.005 and *r* = 0.43 (Fig 5).

**Discussion**

The main result here is the positive correlation of systemic inflammation biomarkers and quadriceps muscle atrophy in COPD patients over 7 days.

The results showed reduced quadriceps depth and increased systemic inflammation biomarkers such as ESR, CRP and PCT. The study further showed that the increased levels of IL-1β, IL-6, and TNF-α were correlated with quadriceps atrophy. A previous study however, has reported a negative association between systemic inflammation markers and quadriceps strength in stable COPD patients [12]. It has already been indicated that inflammation in COPD patients can be explained by the elevation of CRP, IL-6, IL-8, and TNF-α in the circulation [20] [21]. The presence of local inflammation is a controversial issue in the management of COPD patients. There is still insufficient evidence supporting that local inflammation exists in the skeletal muscle of patients with COPD [22]. For example, according to an early investigation, the peripheral muscles atrophy of COPD patients have been detected by an increase in the TNF-α expression [23]. While none of the other investigators has reproduced these finding [24],[25]. Muscle proteolysis and inhibition of protein synthesis that
may be a consequence of systemic inflammation may be responsible for skeletal muscle dysfunction [26]. The source of these circulating cytokines in muscles is thought to be either of systemic inflammation, activated leukocytes, and/or organ systems such as bone marrow or skeletal muscle itself [27]. Experiments have shown a causal link of inflammatory markers, such as high circulating levels of TNF-α [28] to muscle wasting which is due to enhanced activity of the ubiquitin proteasome pathway [29] or to the apoptosis induction [30]. Directly by compromising contractile function TNF-α may also function as a muscle regulator [31]. In line with these findings, we demonstrated a marked relationship between systemic TNF-α levels and quadriceps strength but not with muscle atrophy.

Similarly, Yende et al [12] showed an inverse correlation between TNF-α and IL-6 levels with quadriceps strength. In that study, despite higher CRP levels in patients, CRP was not an independent predictor of quadriceps strength [13]. These observations support the notion that impairment in quadriceps muscle strength may be mediated through increased systemic inflammatory markers in patients with COPD. When comparing patients with mild/moderate COPD with those with severe/very severe disease, no difference was found between the groups, though a tendency to lower quadriceps depth was observed in severe and very severe patients.

Finally, it is necessary to point out that the current study had limitations. For example, it's better to be able to muscle strength by using the method one-repetition maximum (1 RM). In addition, we could examine more muscle or examine more specialized inflammatory mediums including different types of cytokines, and we could even evaluate the interactions between inflammatory markers and muscle weakness. In summary, our results are suggestive of an association between
systemic inflammation markers and quadricep muscle atrophy in individuals with COPD.

Declarations

Acknowledgment
This is a report of a database from a thesis entitled “Relationship between onset of Quadriceps muscle atrophy with inflammatory markers among COPD patients under mechanical Ventilation” registered in the Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran.

Authors' contributions
MN wrote the manuscript and patients selected and management. MG contributed to wrote the paper and helped with ELISA tests. HM helped in the project design. MT contributed to the measurement of quadriceps muscle depth. MA Supervised the project and performed the statistical analysis. HV contributed to the interpretation patients management and helped in the project design.

Funding
Not applicable.

Availability of data and materials
The data that support the findings of this project are accessible on request from the corresponding author. The data are not publicly accessible due to privacy or ethical limitations.

Consent for publication
All authors read the paper and approval for its publication.

Competing interests
The authors declare that there is no conflict of interest regarding the publication of
Ethics approval and consent to participate

Each participant signed a written informed consent form and was made aware of the study procedures based on ethical approval by the Research Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1396.134)

References

1. Society AT: Skeltal muscle dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999, **159**:S1-S40.

2. Gosselink R, Troosters T, Decramer M: Peripheral muscle weakness contributes to exercise limitation in COPD. *American journal of respiratory and critical care medicine* 1996, **153**(3):976-980.

3. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G: Muscle weakness is related to utilization of health care resources in COPD patients. *European Respiratory Journal* 1997, **10**(2):417-423.

4. Man WD, Soliman M, Nikoletou D, Harris M, Rafferty G, Mustfa N, Polkey M, Moxham J: Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. *Thorax* 2003, **58**(8):665-669.

5. Polkey MI, Moxham J: Attacking the disease spiral in chronic obstructive pulmonary disease. *Clinical Medicine* 2006, **6**(2):190-196.

6. Spruit MA, Pennings H-J, Janssen PP, Does JD, Scroyen S, Akkermans MA, Mostert R, Wouters EF: Extra-pulmonary features in COPD patients entering rehabilitation after stratification for MRC dyspnea grade. *Respiratory medicine* 2007, **101**(12):2454-2463.
7. Simpson K, Killian K, McCartney N, Stubbing D, Jones N: **Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation.** *Thorax* 1992, 47(2):70-75.

8. Gruffydd-Jones K, Loveridge C: **The 2010 NICE COPD Guidelines: how do they compare with the GOLD guidelines?** *Primary care respiratory journal: journal of the General Practice Airways Group* 2011, 20(2):199-204.

9. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: **C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 2007, 175(3):250-255.

10. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: **C-reactive protein in patients with COPD, control smokers and non-smokers.** *Thorax* 2006, 61(1):23-28.

11. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM: **Raised CRP levels mark metabolic and functional impairment in advanced COPD.** *Thorax* 2006, 61(1):17-22.

12. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M et al: **Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects.** *Thorax* 2006, 61(1):10-16.

13. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G: **The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD).** *Primary care respiratory journal: journal of the General Practice Airways Group* 2007, 16(4):236-240.

14. Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, Tomoike H: **The relationship between chronic hypoxemia and activation...**
of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161(4 Pt 1):1179-1184.

15. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M: Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003, 58(9):752-756.

16. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F: Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158(2):629-634.

17. Hopkinson NS, Tennant RC, Dayer MJ, Swallow EB, Hansel TT, Moxham J, Polkey MI: A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respiratory research 2007, 8:25.

18. Meijer K, Annegarn J, Lima Passos V, Savelberg HH, Schols AM, Wouters EF, Spruit MA: Characteristics of daily arm activities in patients with COPD. The European respiratory journal 2014, 43(6):1631-1641.

19. de Bruin PF, Ueki J, Watson A, Pride NB: Size and strength of the respiratory and quadriceps muscles in patients with chronic asthma. The European respiratory journal 1997, 10(1):59-64.

20. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I: Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. Journal of inflammation (London, England) 2010, 7:29.

21. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E et al: Persistent systemic inflammation
is associated with poor clinical outcomes in COPD: a novel phenotype. 

*PloS one* 2012, 7(5):e37483.

22. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, Dekhuijzen PN, Franssen F, Gayan-Ramirez G, Gea J *et al*: **An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 2014, 189(9):e15-62.

23. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernandez N, Talamo C: **Skeletal muscle inflammation and nitric oxide in patients with COPD.** *The European respiratory journal* 2005, 26(3):390-397.

24. Barker BL, McKenna S, Mistry V, Pancholi M, Patel H, Haldar K, Barer MR, Pavord ID, Steiner MC, Brightling CE *et al*: **Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease.** *International journal of chronic obstructive pulmonary disease* 2014, 9:975-981.

25. Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, Coronell C, Gea J: **Cytokine profile in quadriceps muscles of patients with severe COPD.** *Thorax* 2008, 63(2):100-107.

26. Degens H, Gayan-Ramirez G, van Hees HW: **Smoking-induced skeletal muscle dysfunction: from evidence to mechanisms.** *Am J Respir Crit Care Med* 2015, 191(6):620-625.

27. Barnes PJ, Celli BR: **Systemic manifestations and comorbidities of COPD.** *The European respiratory journal* 2009, 33(5):1165-1185.

28. Tang K, Wagner PD, Breen EC: **TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke**
exposure. Journal of cellular physiology 2010, 222(2):320-327.

29. Langen RC, Schols AM, Kelders MC, van der Velden JL, Wouters EF, Janssen-Heininger YM: **Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation.** American journal of respiratory cell and molecular biology 2006, 35(6):689-696.

30. Carbo N, Busquets S, van Royen M, Alvarez B, Lopez-Soriano FJ, Argiles JM: **TNF-alpha is involved in activating DNA fragmentation in skeletal muscle.** British journal of cancer 2002, 86(6):1012-1016.

31. Reid MB, Lannergren J, Westerblad H: **Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments.** Am J Respir Crit Care Med 2002, 166(4):479-484.

Tables

Table 1. Demographic data of patients (n = 40)

| Characteristic                  |        |
|--------------------------------|--------|
| Number of patients             | 40     |
| Age (years)                    | 65.83±15.6 |
| Gender, male/female            | 23/17  |
| BMI                            | 25.54±5.43 |

Table 2. The results of inflammatory factors evaluation and quadriceps muscle atrophy in COPD patients over 7 days

|                      | First time       | Second time      | Third time       | P value 1 vs 2 | P value 1 vs 3 |
|----------------------|------------------|------------------|------------------|----------------|----------------|
| ESR (mm)             | 54.43±27.06      | 41.83±20.65      | 37.15±14.66      | 0.025          | 0.0013         |
| CRP                  | 37.4±18.02       | 28.14±16.29      | 26.25±11.26      | 0.022          | 0.0046         |
| PCT                  | 14.19±17.98      | 7.34±6.516       | 6.92±6.27        | 0.025          | 0.016          |
| IL-1b (pg/ml)        | 14.43±8.04       | 13.79±6.61       | 16.1±9.02        | 0.93           | 0.41           |
| IL-6 (pg/ml)         | 3.96±2.24        | 3.65±1.86        | 4.25±2.44        | 0.82           | 0.85           |
| TNF-α (pg/ml)        | 167.9±65.08      | 155.6±85.12      | 194.7±99.61      | 0.77           | 0.39           |
| Muscle Depth         | 20.26±6.976      | 16.64±6.248      | 14.33±5.179      | 0.031          | 0.0008         |

Figures
Figure 1

Ultrasonography was performed to obtain the degree of atrophy of the quadriceps:

Figure 2

The results of inflammatory factors evaluation, statistical analysis showed a stati
The results of proinflammatory cytokine evaluation, there was no statistically significant difference in the secretion level of proinflammatory cytokine.

Figure 3

The results of correlation between various inflammatory factors and quadriceps muscle atrophy showed a positive correlation between the quadriceps atrophy of COPD patients and the early rate of ESR, CRP, and PCT.

Figure 4

The results of correlation between proinflammatory cytokine and quadriceps muscle atrophy.